| NEXTPLAT |
NEXTPLAT |
90%
|
The Company and NextPlat amended the agreement in October 2024 to extend the term of the agreement to 2026, and permit NextPlat to launch an online storefront on additional e-commerce platforms throu… |
| NIMU |
Non-Invasive Monitoring Systems, Inc. |
90%
|
Reciprocal relationship from NIMU graph: Reciprocal relationship from OPK graph: Reciprocal relationship from NIMU graph: One of those related parties, OPKO Health, Inc. ("OPKO") and the Company are … |
| OPKO-HEALTH-EUROPE-SLU |
OPKO-HEALTH-EUROPE-SLU |
90%
|
The Company launched an OPKO Health-branded online storefront on the Alibaba Group Holding Limited Tmall Global e-commerce platform in China, featuring an assortment of nutraceutical and veterinary p… |
| LLY |
Eli Lilly and Company |
85%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from OPK graph: Reciprocal relationship from LLY graph: Reciprocal relationship from OPK graph: Reciprocal relationship from LLY graph:… |
| LLY |
Eli Lilly and Company |
85%
|
6, through its subsidiary Waratah Pharmaceuticals Inc., entered into a worldwide license agreement with Eli Lilly and Company (“Eli Lilly”) to develop and commercialize certain oxyntomodulin-based co… |
| ASND |
Ascendis Pharma A/S |
72%
|
aboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substantially greater financial and other resources, larger research and development staf… |
| ASND |
Ascendis Pharma A/S |
72%
|
Reciprocal relationship from ASND graph: Reciprocal relationship from OPK graph: Reciprocal relationship from ASND graph: Reciprocal relationship from OPK graph: Reciprocal relationship from ASND gra… |
| CAMP |
CAMP4 THERAPEUTICS CORPORATION |
72%
|
Reciprocal relationship from CAMP graph: Reciprocal relationship from OPK graph: ence over the particular investee and whether the particular equity security has a readily determinable fair value. We… |
| CAMP |
CAMP4 THERAPEUTICS CORPORATION |
72%
|
ence over the particular investee and whether the particular equity security has a readily determinable fair value. We have determined that our ownership in these entities, along with that of related… |
| COCP |
Cocrystal Pharma, Inc. |
72%
|
ence over the particular investee and whether the particular equity security has a readily determinable fair value. We have determined that our ownership in these entities, along with that of related… |
| COCP |
Cocrystal Pharma, Inc. |
72%
|
Reciprocal relationship from COCP graph: Reciprocal relationship from OPK graph: Reciprocal relationship from COCP graph: Reciprocal relationship from OPK graph: Reciprocal relationship from COCP gra… |
| ELOX |
ELOX |
72%
|
Reciprocal relationship from ELOX graph: Reciprocal relationship from OPK graph: Reciprocal relationship from ELOX graph: Reciprocal relationship from OPK graph: Reciprocal relationship from ELOX gra… |
| ELOX |
ELOX |
72%
|
ence over the particular investee and whether the particular equity security has a readily determinable fair value. We have determined that our ownership in these entities, along with that of related… |
| NAGE |
Niagen Bioscience, Inc. |
72%
|
Reciprocal relationship from NAGE graph: Reciprocal relationship from OPK graph: Reciprocal relationship from NAGE graph: Reciprocal relationship from OPK graph: ence over the particular investee and… |
| NAGE |
Niagen Bioscience, Inc. |
72%
|
ence over the particular investee and whether the particular equity security has a readily determinable fair value. We have determined that our ownership in these entities, along with that of related… |
| NIMU |
Non-Invasive Monitoring Systems, Inc. |
72%
|
ence over the particular investee and whether the particular equity security has a readily determinable fair value. We have determined that our ownership in these entities, along with that of related… |
| NVO |
Novo Nordisk A/S |
72%
|
aboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substantially greater financial and other resources, larger research and development staf… |
| NVO |
Novo Nordisk A/S |
72%
|
Reciprocal relationship from NVO graph: Reciprocal relationship from OPK graph: Reciprocal relationship from NVO graph: Reciprocal relationship from OPK graph: Reciprocal relationship from NVO graph:… |
| ONCO |
Onconetix, Inc. |
72%
|
Reciprocal relationship from ONCO graph: me of which possess substantially greater financial, selling, logistical and laboratory resources, more experience in dealing with third-party payors, and gre… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from OPK graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from OPK graph: Reciprocal relationship from SNYNF … |
| SNYNF |
Sanofi |
72%
|
stinct within the contract and provides standalone value. Similarly, the exercised option to develop a multispecific protein antibody for influenza or another pathogen is also a separate performance … |
| WGS |
GeneDx Holdings Corp. |
72%
|
t, and lower costs related to Somatrogon (hGH-CTP) following the closure of open-label extension studies in countries where it has received marketing authorization. Contingent consideration . Conting… |
| WGS |
GeneDx Holdings Corp. |
72%
|
Reciprocal relationship from WGS graph: Reciprocal relationship from OPK graph: t, and lower costs related to Somatrogon (hGH-CTP) following the closure of open-label extension studies in countries w… |
| WGSWW |
WGSWW |
72%
|
lated to Somatrogon (hGH-CTP) following the closure of open-label extension studies in countries where it has received marketing authorization. Contingent consideration . Contingent consideration for… |
| WGSWW |
WGSWW |
72%
|
Reciprocal relationship from WGSWW graph: Reciprocal relationship from OPK graph: lated to Somatrogon (hGH-CTP) following the closure of open-label extension studies in countries where it has receive… |
| XBIO |
Xenetic Biosciences, Inc. |
72%
|
ence over the particular investee and whether the particular equity security has a readily determinable fair value. We have determined that our ownership in these entities, along with that of related… |
| XBIO |
Xenetic Biosciences, Inc. |
72%
|
Reciprocal relationship from XBIO graph: Reciprocal relationship from OPK graph: Reciprocal relationship from XBIO graph: Reciprocal relationship from OPK graph: ence over the particular investee and… |
| ELI-LILLY-AGREEMENT-NICOYA-MACAU-LIMITED |
ELI-LILLY-AGREEMENT-NICOYA-MACAU-LIMITED |
62%
|
s subsidiary Waratah Pharmaceuticals Inc., entered into a worldwide license agreement with Eli Lilly and Company (“Eli Lilly”) to develop and commercialize certain oxyntomodulin-based compounds, whic… |
| ENTERA-BIO-LTD |
ENTERA-BIO-LTD |
62%
|
lopment or commercial supply at the licensee’s election. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at t… |
| MODEX-THERAPEUTICS-INC |
MODEX-THERAPEUTICS-INC |
62%
|
rovisions of the PSLRA. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Risks and unc… |
